Jefferies Group LLC currently has a $13.00 price target on the stock, up from their previous price target of $11.00. Several other analysts have also issued reports on PGNX.

Shares of Progenics Pharmaceuticals Inc. have been given an average rating of “Buy” by the seven research firms that are currently covering the firm. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company.